Reuben Benjamin

机构：London Cancer, King's College Hospital NHS Foundation Trust, King's College Hospital · ORCID：0000-0003-1434-0594

发表论文 146 篇 · 总被引 4449 次 · h-index 32

代表论文

• Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations (2023 · Blood · 被引 349)
• Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses (2024 · Blood · 被引 75)
• Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma (2023 · Journal of Clinical Investigation · 被引 62)
• LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis) (2024 · Leukemia · 被引 37)
• Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study (2023 · The Lancet Oncology · 被引 30)
• Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial (2022 · The Lancet Haematology · 被引 25)